Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Sanofi's 2-Pen Diabetes Combo Perplexes FDA

Executive Summary

Sanofi SA's strategy of using two pen injectors for its fixed-ratio combination that combines its experimental glucagon-like peptide-1 receptor agonist lixisenatide with its US-approved diabetes drug Lantus (basal insulin glargine) has the FDA perplexed and concerned about the potential for adverse events and medication errors.

Advertisement

Related Content

FDA On Novo's Diabetes Combo: It's Complicated
Sanofi Files LixiLan For Diabetes, Gambles Expensive Priority Review Voucher
Lantus Follow-On Basaglar OK'd, But Can Lilly Sell It?
Sanofi paying big for FDA voucher; Retrophin snags $245m

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register